AU2014287427B2 - Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist - Google Patents

Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist Download PDF

Info

Publication number
AU2014287427B2
AU2014287427B2 AU2014287427A AU2014287427A AU2014287427B2 AU 2014287427 B2 AU2014287427 B2 AU 2014287427B2 AU 2014287427 A AU2014287427 A AU 2014287427A AU 2014287427 A AU2014287427 A AU 2014287427A AU 2014287427 B2 AU2014287427 B2 AU 2014287427B2
Authority
AU
Australia
Prior art keywords
endothelin
receptor agonist
compositions
methods
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014287427A
Other languages
English (en)
Other versions
AU2014287427A1 (en
Inventor
Anil Gulati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midwestern University Glendale
Original Assignee
Midwestern University Downers Grove
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midwestern University Downers Grove, Midwestern University Glendale filed Critical Midwestern University Downers Grove
Publication of AU2014287427A1 publication Critical patent/AU2014287427A1/en
Application granted granted Critical
Publication of AU2014287427B2 publication Critical patent/AU2014287427B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2014287427A 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist Active AU2014287427B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843702P 2013-07-08 2013-07-08
US61/843,702 2013-07-08
US201361902935P 2013-11-12 2013-11-12
US61/902,935 2013-11-12
PCT/US2014/045748 WO2015006324A2 (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Publications (2)

Publication Number Publication Date
AU2014287427A1 AU2014287427A1 (en) 2016-02-11
AU2014287427B2 true AU2014287427B2 (en) 2019-11-21

Family

ID=52280704

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014287427A Active AU2014287427B2 (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist

Country Status (10)

Country Link
US (2) US10561704B2 (enExample)
EP (1) EP3019242B1 (enExample)
JP (2) JP6928450B2 (enExample)
CN (2) CN105682741A (enExample)
AU (1) AU2014287427B2 (enExample)
BR (1) BR112016000431A8 (enExample)
CA (2) CA2917325C (enExample)
ES (1) ES2825101T3 (enExample)
PL (1) PL3019242T3 (enExample)
WO (1) WO2015006324A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759791C (en) 2009-04-30 2018-04-10 Midwestern University Novel therapeutic treatments using centhaquin
BR112020022395A2 (pt) * 2018-05-03 2021-04-13 Midwestern University Alterações em receptores de endotelina em seguida a hemorragia e ressuscitação por centaquina
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
AU2024262867A1 (en) * 2023-04-26 2025-12-04 Biocells (Beijing) Biotech Co., Ltd. Polypeptide and use thereof
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043654A2 (en) * 2000-12-01 2002-06-06 Milos Pekny Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions
WO2003009805A2 (en) * 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis
WO2009026828A1 (en) * 2007-08-22 2009-03-05 Huawei Technologies Co., Ltd. Method and apparatus for implementing multimedia color ring service and multimedia color image service
US20120093798A1 (en) * 2007-08-21 2012-04-19 Midwestern University Methods for Treatment of Stroke or Cerebrovascular
WO2012138043A2 (en) * 2011-04-04 2012-10-11 Seoul National University Hospital Therapeutic composition containing endothelin as an active component

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
US20040138121A1 (en) 2002-10-24 2004-07-15 Anil Gulati Method and composition for preventing and treating solid tumors
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
CN101405020A (zh) 2006-03-23 2009-04-08 安米林药品公司 代谢疾病治疗中的内皮素和内皮素受体激动剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043654A2 (en) * 2000-12-01 2002-06-06 Milos Pekny Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions
WO2003009805A2 (en) * 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis
US20120093798A1 (en) * 2007-08-21 2012-04-19 Midwestern University Methods for Treatment of Stroke or Cerebrovascular
WO2009026828A1 (en) * 2007-08-22 2009-03-05 Huawei Technologies Co., Ltd. Method and apparatus for implementing multimedia color ring service and multimedia color image service
WO2012138043A2 (en) * 2011-04-04 2012-10-11 Seoul National University Hospital Therapeutic composition containing endothelin as an active component

Also Published As

Publication number Publication date
AU2014287427A1 (en) 2016-02-11
EP3019242A4 (en) 2017-01-25
JP6928450B2 (ja) 2021-09-01
US10561704B2 (en) 2020-02-18
WO2015006324A3 (en) 2015-11-05
US20200353031A1 (en) 2020-11-12
CN113384701A (zh) 2021-09-14
EP3019242B1 (en) 2020-08-19
PL3019242T3 (pl) 2021-02-08
JP7385924B2 (ja) 2023-11-24
CN105682741A (zh) 2016-06-15
CA2917325A1 (en) 2015-01-15
JP2016523969A (ja) 2016-08-12
ES2825101T3 (es) 2021-05-14
CA3171883A1 (en) 2015-01-15
JP2021020945A (ja) 2021-02-18
WO2015006324A2 (en) 2015-01-15
BR112016000431A8 (pt) 2018-01-23
US20160151450A1 (en) 2016-06-02
EP3019242A2 (en) 2016-05-18
CA2917325C (en) 2023-09-05
WO2015006324A8 (en) 2016-01-28
CA3171883C (en) 2024-03-05

Similar Documents

Publication Publication Date Title
PH12020500286A1 (en) Use of agonists of formly peptide receptor 2 for treating ocular inflammatory diseases
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
MX2016005560A (es) Compuestos agonistas triples de glucagon-glp-1-gip.
MX2021015234A (es) Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
TN2016000057A1 (en) Methods of treating sporadic inclusion body myositis
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
SG11202102349PA (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
AU2014287427B2 (en) Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
TW201713333A (en) Methods of treating a neurodegenerative disease
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
HK1216300A1 (zh) 作为crac通道抑制剂的基於吡唑基的甲醯胺i
PH12013500471A1 (en) Compound composition for inhalation used for treating asthma
BR112015016394A2 (pt) carboxamidas ii baseadas em pirazolil como inibidoras do canal crac
IN2013MU03428A (enExample)
WO2015051234A3 (en) Tweak antagonists for treating lupus nephritis and muscle atrophy
HK1227697A1 (en) Tweak antagonists for treating lupus nephritis and muscle atrophy
HK1221666A1 (zh) 氨基吡啶用於治疗与某些中风类型相关的视觉障碍的方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)